Ginsenoside compound K exerts antitumour effects in renal cell carcinoma via regulation of ROS and lncRNA THOR

Chen,Shuqiu; Ye,Haihong; Gong,Fanger; Mao,Suming; Li,Cong; Xu,Bin; Ren,Yu; Yu,Rui

doi:10.3892/or.2021.7989

Ginsenoside compound K exerts antitumour effects in renal cell carcinoma via regulation of ROS and lncRNA THOR

Authors:
- Shuqiu Chen
- Haihong Ye
- Fanger Gong
- Suming Mao
- Cong Li
- Bin Xu
- Yu Ren
- Rui Yu
View Affiliations

Affiliations: Department of Urology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Urology, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315100, P.R. China, Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School, Ningbo University, Ningbo, Zhejiang 315210, P.R. China
Published online on: February 22, 2021 https://doi.org/10.3892/or.2021.7989
Article Number: 38
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is a common type of kidney cancer that lacks effective therapeutic options. Ginsenoside compound K (CK), an active metabolite of ginsenosides, has been reported to induce apoptosis in various types of cancer cells. However, the effects of CK in RCC remain to be elucidated. Thus, the aim of the present study was to investigate the antitumor effects of CK on RCC cells. The effects of CK on the proliferation, migration, invasion, cell cycle and apoptosis of RCC cell lines (Caki‑1 and 768‑O) were investigated using MTT, wound healing, Transwell and flow cytometry assays, respectively. Changes in the expression levels of long non‑coding RNAs (lncRNAs) and proteins were measured via reverse transcription‑quantitative PCR and western blotting, respectively. Transfections with testis associated oncogenic (THOR) small interfering RNA and pcDNA were performed to knock down and overexpress lncRNA THOR, respectively. It was found that CK could effectively inhibit the proliferation, migration and invasion of RCC cells. CK also induced cell cycle arrest and caspase‑dependent apoptosis in RCC cells. Furthermore, the generation of reactive oxygen species and inhibition of the lncRNA THOR played important roles in the antitumour effects of CK in RCC cells. The present data revealed that CK was a potent antitumour agent against RCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Motzer RJ, Bander NH and Nanus DM: Renal-Cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
3	Fontana F, Raimondi M, Marzagalli M, Di Domizio A and Limonta P: The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochim Biophys Acta Rev Cancer. 1873:1883382020. View Article : Google Scholar : PubMed/NCBI
4	Cho CW, Kim YC, Kang JH, Rhee YK, Choi SY, Kim KT, Lee YC and Hong HD: Characteristic study on the chemical components of Korean curved ginseng products. J Ginseng Res. 37:349–354. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yang XD, Yang YY, Ouyang DS and Yang GP: A review of biotransformation and pharmacology of ginsenoside compound K. Fitoterapia. 100:208–220. 2015. View Article : Google Scholar : PubMed/NCBI
6	Gan XT and Karmazyn M: Cardioprotection by ginseng: Experimental and clinical evidence and underlying mechanisms. Can J Physiol Pharmacol. 96:859–868. 2018. View Article : Google Scholar : PubMed/NCBI
7	Oh J and Kim JS: Compound K derived from ginseng: Neuroprotection and cognitive improvement. Food Funct. 7:4506–4515. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hasegawa H, Sung JH, Matsumiya S and Uchiyama M: Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 62:453–457. 1996. View Article : Google Scholar : PubMed/NCBI
9	Kim H, Roh HS, Kim JE, Park SD, Park WH and Moon JY: Compound K attenuates stromal cell-derived growth factor 1 (SDF-1)-induced migration of C6 glioma cells. Nutr Res Pract. 10:259–264. 2016. View Article : Google Scholar : PubMed/NCBI
10	Lee S, Kwon MC, Jang JP, Sohng JK and Jung HJ: The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells. Int J Oncol. 51:414–424. 2017. View Article : Google Scholar : PubMed/NCBI
11	Shin DH, Leem DG, Shin JS, Kim JI, Kim KT, Choi SY, Lee MH, Choi JH and Lee KT: Compound K induced apoptosis via endoplasmic reticulum Ca²⁺ release through ryanodine receptor in human lung cancer cells. J Ginseng Res. 42:165–174. 2018. View Article : Google Scholar : PubMed/NCBI
12	Chen HF, Wu LX, Li XF, Zhu YC, Wang WX, Xu CW, Huang ZZ and Du KQ: Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1α-mediated glucose metabolism. Cell Mol Biol (Noisy-le-grand). 65:48–52. 2019. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Xu Y, Zhu Y and Li X: Anti-Cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells. Cancer Cell Int. 13:242013. View Article : Google Scholar : PubMed/NCBI
14	Law CK, Kwok HH, Poon PY, Lau CC, Jiang ZH, Tai WC, Hsiao WW, Mak NK, Yue PY and Wong RN: Ginsenoside compound K induces apoptosis in nasopharyngeal carcinoma cells via activation of apoptosis-inducing factor. Chin Med. 9:112014. View Article : Google Scholar : PubMed/NCBI
15	Wang CZ, Du GJ, Zhang Z, Wen XD, Calway T, Zhen Z, Musch MW, Bissonnette M, Chang EB and Yuan CS: Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol. 40:1970–1976. 2012.PubMed/NCBI
16	Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng Y and Ma Q: Anti-Tumor effects of atractylenolide I on bladder cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, Bennett R, et al: Ensemble 2020. Nucleic Acids Res. 48:D682–D688. 2020.PubMed/NCBI
19	Martinotti S and Ranzato E: Scratch wound healing assay. Methods Mol Biol. 2109:225–229. 2020. View Article : Google Scholar : PubMed/NCBI
20	American Association for Laboratory Animal Science, . AALAS position statement on the humane care and use of laboratory animals. Com Med. 4:4132007.
21	Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C and Czarnecka AM: Choosing the right cell line for renal cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
22	Oh JM, Kim E and Chun S: Ginsenoside compound K induces ros-mediated apoptosis and autophagic inhibition in human neuroblastoma cells in vitro and in vivo. Int J Mol Sci. 20:42792019. View Article : Google Scholar
23	Kim AD, Kang KA, Kim HS, Kim DH, Choi YH, Lee SJ, Kim HS and Hyun JW: A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis. 4:e7502013. View Article : Google Scholar : PubMed/NCBI
24	Qi LW, Wang CZ, Du GJ, Zhang ZY, Calway T and Yuan CS: Metabolism of ginseng and its interactions with drugs. Curr Drug Metab. 12:818–822. 2011. View Article : Google Scholar : PubMed/NCBI
25	Paek IB, Moon Y, Kim J, Ji HY, Kim SA, Sohn DH, Kim JB and Lee HS: Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharm Drug Dispos. 27:39–45. 2006. View Article : Google Scholar : PubMed/NCBI
26	Zhang X, Zhang S, Sun Q, Jiao W, Yan Y and Zhang X: Compound K induces endoplasmic reticulum stress and apoptosis in human liver cancer cells by regulating STAT3. Molecules. 19:14822018. View Article : Google Scholar
27	Yao H, Wan JY, Zeng J, Huang WH, Sava-Segal C, Li L, Niu X, Wang Q, Wang CZ and Yuan CS: Effects of compound K, an enteric microbiome metabolite of ginseng, in the treatment of inflammation associated colon cancer. Oncol Lett. 15:8339–8348. 2018.PubMed/NCBI
28	Zhang K and Li Y: Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer. Pharm Biol. 54:561–568. 2016. View Article : Google Scholar : PubMed/NCBI
29	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
30	Piva F, Giulietti M, Santoni M, Occhipinti G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G and Montironi R: Epithelial to mesenchymal transition in renal cell carcinoma: Implications for cancer therapy. Mol Diagn Ther. 20:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
31	Boice A and Bouchier-Hayes L: Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res. 1867:1186882020. View Article : Google Scholar : PubMed/NCBI
32	Vallejo MJ, Salazar L and Grijalva M: Oxidative stress modulation and ROS-mediated toxicity in cancer: A review on in vitro models for plant-derived compounds. Oxid Med Cell Longev. 2017:45860682017. View Article : Google Scholar : PubMed/NCBI
33	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
34	Ye XT, Huang H, Huang WP and Hu WL: LncRNA THOR promotes human renal cell carcinoma cell growth. Biochem Biophys Res Commun. 501:661–667. 2018. View Article : Google Scholar : PubMed/NCBI